Oxford BioDynamics (LON:OBD) Hits New 1-Year Low – Should You Sell?

Oxford BioDynamics Plc (LON:OBD)’s share price hit a new 52-week low during trading on Monday . The company traded as low as GBX 0.37 ($0.00) and last traded at GBX 0.39 ($0.01), with a volume of 8083034 shares traded. The stock had previously closed at GBX 0.43 ($0.01).

Analysts Set New Price Targets

Separately, Shore Capital reissued a “house stock” rating on shares of Oxford BioDynamics in a research note on Thursday, March 13th.

Oxford BioDynamics Stock Performance

The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The firm’s 50-day moving average price is GBX 0.50 and its two-hundred day moving average price is GBX 1.13. The stock has a market cap of £8.05 million, a price-to-earnings ratio of -0.07 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings results on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.